Recent

% | $
Quotes you view appear here for quick access.

Endocyte, Inc. (ECYT) Message Board

  • seriousjust seriousjust Oct 27, 2012 3:46 PM Flag

    4 new threatments EC145 Vintafolide, paid and developed by Merck, which ones, ...?

    anyone idea(s) which of the below threatment(s) Merck will start as pacakage deal of 4 new threatment(s) of Vintafolide?

    - Liver
    - Endometrial
    - Breast
    - Testicular
    - Prostate
    - Brain
    - Bladder
    - Gastric
    - Colorectal
    - Pancreas
    - Kidney

    My guess is the following 4:

    - Breast
    - Endometrial
    - Colorectal
    - Liver

    Any thoughts?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Targeted therapies that have are positive for associated test for folate effectiveness. FDA is very happy to open the path for a targeted therapy where a company can identify patients likely to respond.
      I'm guessing Merck will do a complete buyout if NSCLC F++ results are looking good.

 
ECYT
6.35+0.18(+2.92%)Apr 20 4:00 PMEDT